We have assessed the frequency of potentially actionable breast cancer gene variants in a large series of women with breast cancer comparing rates of detection of non-BRCA PVs with BRCA1/2 at different BRCA1/2 likelihood scores. This evidence concerns the gene BRCA1 and breast cancer.